SGN-ALPV is under clinical development by Seagen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGN-ALPV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SGN-ALPV overview

SGN-ALPV is under development for the treatment of solid tumors, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), gastric cancer, gastroesophageal junction carcinomas, cervical cancer, malignant testicular germ cell tumor and hematological malignancies. It is administered through intravenous route. It is an antibody drug conjugate (ADC). It acts by targeting cells expressing alkaline phosphatase placental type (ALPP) and alkaline phosphatase placental-like 2 (ALPPL2).

Seagen overview

Seagen, formerly Seattle Genetics, is a biotechnology company focused on the discovery, development, and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company markets antibody-drug conjugates (ADCs) designed to target specific types of cancer. These includes Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas, and CD30 expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs in blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology and SEA technology which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.

For a complete picture of SGN-ALPV’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.